NEW YORK--(BUSINESS WIRE)--IntelliCell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“IntelliCell”) or the (“Company”), IntelliCell has licensed its proprietary, patent pending technology for the manufacture of stromal vascular fraction from adipose tissue to RegenaStem Inc., a Canadian Federally Incorporated Company, with offices located at 13 King Street West Stoney Creek, Ontario, Canada L8G1G9. The license calls for investing a minimum of $500,000 to a maximum of $1.5 million into IntelliCell BioSciences and paying royalties of 30% of net revenue.
IntelliCell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue. This process dramatically increases the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods in use today. IntelliCell’s process generates between half billion - 1.4 billion SVFC cells from 60 ccs from a patient’s own adipose tissue. This is approximately 10-20 times greater than enzyme based methods. Dr. Steven Victor, CEO, IntelliCell BioSciences said “the licensing partnership with IntelliCell BioSciences Canada will enable us to rapidly penetrate the Canadian market using the same strategies that are being implemented in the United States. We are very excited to be working with the individuals behind IntelliCell BioSciences of Canada as they have excellent experience with stromal vascular fraction.”
IntelliCell BioSciences of Canada is a Company headquartered in Ontario Canada servicing the burgeoning regenerative medicine market by providing innovative IntelliCell technology to the Canadian marketplace. “We expect a rapid acceptance of the use for non-enzymatic stromal vascular fraction in the Canadian market. We are looking forward to establishing numerous IntelliCell Centers of Excellence throughout the various Canadian providences,” said Dr. Nick Vaccaro.
The following are the backgrounds of Principals for RegenaStem and IntelliCell BioSciences of Canada:
Mr. Jason Kane, President and Founder
After completing a Business and Marketing degree, at the young age of 21 he created and successfully launched the first online web directory in Hamilton called HamiltonWeb which was to become 701.com. Jason Kane also launched Evolutionary Web Designs. This company develops strategic web models for brick and mortar businesses to allow them to succeed online. A pioneering entrepreneur, Jason Kane founded MediVet Canada Inc. and was President and CEO for the past 2 years. He spearheaded the launch of the first in-clinic stem cell therapy kits for veterinarians in Canada and, at the time, the company was the first and only company to establish and provide such services. Jason Kane was trained in the U.S.A. by some of the best veterinarians in the field and is considered an expert in delivering this type of stem cell therapy.
Dr. Nick Vaccaro D.C., C.S.C.S., Chief Executive Officer
Dr. Nick Vaccaro graduated from the Canadian Memorial Chiropractic College in 1983 and has maintained a successful private practice in the Niagara Falls area for 28 years. Dr. Vaccaro has successfully developed numerous early stage companies that have brought product from conception to marketplace. From 2003 to 2004, he spearheaded the attempt to re-launch the World Hockey Association with International attention. Dr. Vaccaro's past business endeavors have provided diverse experiences and knowledge and combined with his clinical back-ground have been the foundation for the creation of the Renaissance Wellness Suites. This new paradigm in adult living that is set to begin construction on its first location in Niagara Falls in 2012 is patent pending and provides residents with multi-dimensional wellness and anti-aging programs combined with clinical documentation of outcomes. The addition of Cellular Regenerative Therapy to the Renaissance Wellness Suites will develop a universally beneficial health care model.
Sandeep (Sonny) Singh Kohli, MD FRCPC
Dr. Sandeep Kohli currently holds the positions of “Chair of the Cardiac Arrest Committee” and “Medical Director of Advanced Cardiac Life Support” for 3 district hospitals (Oakville, Milton & Georgetown). At a provincial level, he also holds several other Medical Director positions for the Heart & Stroke Foundation’s ACLS, specifically at the Michener Institute in Toronto, and at St. Mary’s regional cardiac care Hospital in Kitchener. As a Physician dedicated to improving health care at a patient level, Dr. Kohli is Royal College certified in both Critical Care Medicine & Internal Medicine, and has practiced at Oakville Trafalgar Memorial Hospital since 2005. As an educator dedicated to improving health care based education, Dr. Kohli is an Assistant Clinical Professor (adjunct) of Medicine at McMaster University. In addition to experience in medical student admissions and testing, he supervises and tests resident physicians and fellows training in Internal Medicine & Critical Care.
Mr. Joseph Trombetta, Chief Financial Officer
With over 20 years in the financial services industry, Joseph Trombetta is also President and founder of Titan Mortgage Group. His expertise in the commercial and residential mortgage sector has given Mr. Trombetta a keen awareness of the nature and complexity of the finance industry today. Given the challenges both corporations and individuals face in today’s economic environment, Mr. Trombetta will be a key asset in helping guide IntelliCell Biosciences of Canada to successfully navigate the murky financial waters of the global marketplace.
About IntelliCell BioSciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioScience in exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.